TruScreen censured, fined for director shortage
The NZ Markets Disciplinary Tribunal says companies need succession planning for directors.
Cervical cancer test developer TruScreen has been censured by the NZ Markets Disciplinary Tribunal for only having one New Zealand resident director for 18 business days.
The tribunal said TruScreen had only one director who was a New Zealand resident following its annual meeting on September
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Dane Ambler
Tue, 13 Feb 2018
Tue, 13 Feb 2018
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
TruScreen censured, fined for director shortage
73309